Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases receiving radium-233 chloride in a double-blind, randomized, phase III trial (ALSYMPCA)

• LEWINGTON V.

収録刊行物

• Eur J Nucl Med Mol Imaging

  Eur J Nucl Med Mol Imaging 39 S304-, 2012

詳細情報

• CRID: 1570854174331561728
• NII論文ID: 20001399163
• データソース種別:
  • CiNii Articles